Alios BioPharma Garners $8,400,000 Series A Financing

  • Feed Type
  • Date
    2/9/2009
  • Company Name
    Alios BioPharma
  • Mailing Address
    101 A Hickey Boulevard South San Francisco, CA 94080
  • Company Description
    Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
  • Website
    http://www.aliosbiopharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,400,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Novo A/S
  • Venture Investor
    Novartis BioVenture Fund
  • Venture Investor
    Roche Venture Fund

By posting a comment, you agree to our terms and conditions.